OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press70810.17650/1818-8346-2009-0-1-29-38HEMATOPOIETIC STEM CELL TRANSPLANTATIONТРАНСПЛАНТАЦИЯ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОКEndothelial injury syndromes after hematopoietic stem cell transplantation: analyzing clinical caseСиндромы эндотелиального повреждения после трансплантации гемопоэтических стволовых клеток: описание клинического случаяSkvortsovaY. V.СкворцоваЮ. В.
Russian Federation

Moscow

Москва

BalashovD. N.БалашовД. Н.
Russian Federation

Moscow

Москва

DjakonovaY. Y.ДьяконоваЮ. Ю.
Russian Federation

Moscow

Москва

DishlevayaZ. M.ДышлеваяЗ. М.
Russian Federation

Moscow

Москва

KurnikovaE. E.КурниковаЕ. Е.
Russian Federation

Moscow

Москва

MyakovaN. V.МяковаН. В.
Russian Federation

Moscow

Москва

NazhimovV. P.НажимовВ. П.
Russian Federation

Moscow

Москва

SkorobogatovaE. V.СкоробогатоваЕ. В.
Russian Federation

Moscow

Москва

ShelikhovaL. N.ШелиховаЛ. Н.
Russian Federation

Moscow

Москва

ShipitsinaI. P.ШипицинаИ. П.
Russian Federation

Moscow

Москва

TrakhtmanP. E.ТрахтманП. Е.
Russian Federation

Moscow

Москва

MaschanA. A.МасчанА. А.
Russian Federation

Moscow

Москва

Federal Research Center of Pediatric Hematology, Oncology, ImmunologyФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии МинздравсоцразвитияRussian Children's Clinical Hospital, Bone Marrow Transplantation Departmentотделение трансплантации костного мозгаRussian Children's Clinical Hospital, Hematological Department 3отделение гематологии №3Russian Children's Clinical Hospital, Bone Marrow Transplantation Departmentотделение трансплантации костного мозгRussian Children's Clinical Hospital, Hematological Department 3отделение гематологии № 3Children's Clinical Hospital, Pathological Departmentпатолого-анатомическое отделение ФГУ Российская детская клиническая больница240220091293824112022241120222009https://oncohematology.abvpress.ru/ongm/article/view/708

Early complications of hematopoietic stem cell transplantation (HSCT) of vascular origin within the first 30-60 days after HSCT, which are resulting from endothelial injury, are an important cause of transplant-associated morbidity and mortality. Authors describe a case report serving as an example of several endothelial syndromes development with overlapping clinical features. Risk factors and therapy approaches of these complications are discussed.

Ранние осложнения трансплантации гемопоэтических стволовых клеток сосудистого характера, возникающие в первые 30—60 дней после ее проведения и связанные с повреждением эндотелия, являются одними из самых тяжелых и приводят к высокой трансплантат-ассоциированной токсичности и смертности. Авторы приводят описание клинического случая, на примере которого представлено развитие нескольких синдромов эндотелиального повреждения с формированием их клинического перекреста. Обсуждаются факторы риска и подходы к лечению данных осложнений.

endothelial injury syndromesallogeneic hematopoietic stem cell transplantation (HSCT)синдромы эндотелиального поврежденияаллогенная трансплантация гемопоэтических стволовых клеток1. The EBMT Handbook. 5th Edition. Haematopoietic Stem Cell Transplantation. 2008 Revised edition. European School of hematology. Paris, France.The EBMT Handbook. 5th Edition. Haematopoietic Stem Cell Transplantation. 2008 Revised edition. European School of hematology. Paris, France.2. Miano M., Faraci M., Dini G., Bordigoni P. Early complications following haematopoietic SCT in children. Bone Marr Transplant 2008;41:39—42.Miano M., Faraci M., Dini G., Bordigoni P. Early complications following haematopoietic SCT in children. Bone Marr Transplant 2008;41:39—42.3. Tesfamariam B., DeFelice A.M. Endothelial injury in the initiation and progression of vascular disorders. Vasc Pharmacol 2007;46(4):229—37.Tesfamariam B., DeFelice A.M. Endothelial injury in the initiation and progression of vascular disorders. Vasc Pharmacol 2007;46(4):229—37.4. Biedermann B., Sahner S., Gregor M. et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359(9323):2078—83.Biedermann B., Sahner S., Gregor M. et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359(9323):2078—83.5. Woywodt A., Scheer J., Hambach L. et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004;103(9):3603—5.Woywodt A., Scheer J., Hambach L. et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004;103(9):3603—5.6. Schots R., Kaufman L., Van Riet I. et al. Proinflammatory cytokines and their role in the development of major transplantrelated complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003;17:1150—6.Schots R., Kaufman L., Van Riet I. et al. Proinflammatory cytokines and their role in the development of major transplantrelated complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003;17:1150—6.7. Tichelli A., Gratwohl A. Vascular endothelium as ≪novel≫ target of graft-versus-host disease. Best Pract Res Clin Haematol 2008;21(2):139—48.Tichelli A., Gratwohl A. Vascular endothelium as ≪novel≫ target of graft-versus-host disease. Best Pract Res Clin Haematol 2008;21(2):139—48.8. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Hematol 2000;64(5): 281—91.Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Hematol 2000;64(5): 281—91.9. Ho V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marr Transplant 2008;41:229—37.Ho V.T., Revta C., Richardson P.G. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marr Transplant 2008;41:229—37.10. Lazarus H.M., McCrae K.R. SOS! Defibrotide to the rescue. Blood 2008;112(10):3924—5.Lazarus H.M., McCrae K.R. SOS! Defibrotide to the rescue. Blood 2008;112(10):3924—5.11. Pegram A.A., Kennedy L.D. Prevention and treatment of veno-occlusive disease. Ann Pharmacother 2001;35(7—8):935—42.Pegram A.A., Kennedy L.D. Prevention and treatment of veno-occlusive disease. Ann Pharmacother 2001;35(7—8):935—42.12. Bulley S.R., Strahm B., Doyle J. et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007;48(7):700—4.Bulley S.R., Strahm B., Doyle J. et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007;48(7):700—4.13. Qureshi A., Marchall L., Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008;50(4):735—6.Qureshi A., Marchall L., Lancaster D. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Pediatr Blood Cancer 2008;50(4):735—6.14. Kaleelrahman M., Eaton J.D., Leeming D. et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology 2003;8(2):91—5.Kaleelrahman M., Eaton J.D., Leeming D. et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology 2003;8(2):91—5.15. Benimetskaya L., Wu S., Voskresenskiy A.M. et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008;112:4343—52.Benimetskaya L., Wu S., Voskresenskiy A.M. et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008;112:4343—52.16. Nurnberger W., Willers R., Burdach S. et al. Risk factors for capillary-leak-age syndrome after bone marrow transplantation. Ann Hematol 1997;74:221—4.Nurnberger W., Willers R., Burdach S. et al. Risk factors for capillary-leak-age syndrome after bone marrow transplantation. Ann Hematol 1997;74:221—4.17. Spitzer T.R. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marr Transplant 2001;27:893—8.Spitzer T.R. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marr Transplant 2001;27:893—8.18. Nishio N., Yagasaki H., Takahashi Y. et al. Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. Pediatr Transplant 2008; Nov 1 [Epub ahead of print].Nishio N., Yagasaki H., Takahashi Y. et al. Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. Pediatr Transplant 2008; Nov 1 [Epub ahead of print].19. Schmid I., Stachel D., Pagel P., Albert M.H. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marr Transplant 2008;14(4):438—44.Schmid I., Stachel D., Pagel P., Albert M.H. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marr Transplant 2008;14(4):438—44.20. Gorac E., Geller N., Srinivasar R. et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marr Transplant 2005;11(7):542—50.Gorac E., Geller N., Srinivasar R. et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marr Transplant 2005;11(7):542—50.21. Afessa B., Tefferi A., Litzow M.R. et al. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:641—5.Afessa B., Tefferi A., Litzow M.R. et al. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:641—5.22. Majhail N.S., Parks K., Defor T.E. et al. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marr Transplant 2006;12(10):1038—46.Majhail N.S., Parks K., Defor T.E. et al. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marr Transplant 2006;12(10):1038—46.23. Pastores S.M., Papadopoulos E., Halpern N.A. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation. Treatment with recombinant factor VIIa. Chest 2003;124:2400—3.Pastores S.M., Papadopoulos E., Halpern N.A. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation. Treatment with recombinant factor VIIa. Chest 2003;124:2400—3.24. Gupta S., Jain A., Warneke C.L. Outcome of alveolar hemorrhage in hematopoietic stem cell transplant recipients. Bone Marr Transplant 2007;40: 71—8.Gupta S., Jain A., Warneke C.L. Outcome of alveolar hemorrhage in hematopoietic stem cell transplant recipients. Bone Marr Transplant 2007;40: 71—8.25. Moake J.L. Thrombotic microangopathies. N Eng J Med 2002;347(8):589—600.Moake J.L. Thrombotic microangopathies. N Eng J Med 2002;347(8):589—600.26. Siami K., Kojouri K., Swisher K.K. et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008;85(1):22—8.Siami K., Kojouri K., Swisher K.K. et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008;85(1):22—8.27. Uderzo C., Bonanomi S., Busca A. et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006;82(5):638—44.Uderzo C., Bonanomi S., Busca A. et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006;82(5):638—44.28. Kojouri K., George G.N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007;19(2):148—54.Kojouri K., George G.N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007;19(2):148—54.29. Fukuda T., Hackman R.C., Guthrie K.A. et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003;102(8):2777—85.Fukuda T., Hackman R.C., Guthrie K.A. et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003;102(8):2777—85.30. Zhu K.E., Hu J.Y., Chen J. et al. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation. Eur J Hematol 2008;81(6):461—6.Zhu K.E., Hu J.Y., Chen J. et al. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation. Eur J Hematol 2008;81(6):461—6.31. Yanik G.A., Ho V.T., Levine J.E. et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008;112(8): 3073—81.Yanik G.A., Ho V.T., Levine J.E. et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008;112(8): 3073—81.32. Chen I.L., Yang S.N., Hsiao C.C. et al. Treatment with high-dose metylprednisolone for hepatic veno-occlusive disease in a child with rabdomyosarcoma. Pediatr neonatol 2008;49(4):141—4.Chen I.L., Yang S.N., Hsiao C.C. et al. Treatment with high-dose metylprednisolone for hepatic veno-occlusive disease in a child with rabdomyosarcoma. Pediatr neonatol 2008;49(4):141—4.